tradingkey.logo
tradingkey.logo
Search

PharmaCyte Biotech Inc

PMCB
Add to Watchlist
0.715USD
-0.026-3.51%
Close 07/02, 13:00ETQuotes delayed by 15 min
7.68MMarket Cap
LossP/E TTM

More Details of PharmaCyte Biotech Inc Company

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

PharmaCyte Biotech Inc Info

Ticker SymbolPMCB
Company namePharmaCyte Biotech Inc
IPO dateSep 11, 2003
CEOSilverman (Joshua N)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 11
Address3960 Howard Hughes Parkway, Suite 500
CityLAS VEGAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code89169
Phone19175952850
Websitehttps://pharmacyte.com/
Ticker SymbolPMCB
IPO dateSep 11, 2003
CEOSilverman (Joshua N)

Company Executives of PharmaCyte Biotech Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan L. Schechter
Mr. Jonathan L. Schechter
Independent Director
Independent Director
132.50K
-45.28%
Mr. Robert Weinstein
Mr. Robert Weinstein
Independent Director
Independent Director
41.25K
--
Mr. Carlos A. Trujillo, CPA
Mr. Carlos A. Trujillo, CPA
Chief Financial Officer
Chief Financial Officer
10.40K
--
Dr. Michael M. Abecassis, M.D.
Dr. Michael M. Abecassis, M.D.
Independent Director
Independent Director
--
--
Mr. Joshua N. (Josh) Silverman
Mr. Joshua N. (Josh) Silverman
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
Interim Chairman of the Board, Interim Chief Executive Officer and Interim President
--
--
Mr. Wayne R. Walker
Mr. Wayne R. Walker
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of PharmaCyte Biotech Inc?

The top five shareholders of PharmaCyte Biotech Inc are: Mr. Jonathan L. Schechter

How many institutions hold shares of PharmaCyte Biotech Inc (PMCB)?

As of 2026Q1, 67 institutions hold shares of PharmaCyte Biotech Inc, with a combined market value of approximately 1.07M, accounting for 9.99% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 347985.00.